Document is current
Any future updates will be listed below
-
Authors
Li, Xinrui https://orcid.org/0009-0000-3751-007X
Xu, Mingyue
Guo, Xin https://orcid.org/0009-0008-2669-5302
Xu, Yanhua https://orcid.org/0009-0002-4906-9802
- License Information
-
More Information
Article History
Received: 11 September 2025
Accepted: 24 January 2026
First Online: 16 February 2026
Declarations
:
: The authors declare no competing interests.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Jinan Maternity Child Careand Hospital. (Date:2023–8-30/NO:IRB KY-23–68). This study identified ADAMTS18 as a novel tumor suppressor in endometrial carcinoma (EC). Its downregulation can serve as a potential diagnostic/prognostic biomarker, correlating with advanced FIGO stage (≥ III) and larger tumors (≥ 2 cm). Critically, ADAMTS18 overexpression suppresses the proliferation, migration, and invasion of EC cells and promotes apoptosis, establishing its therapeutic potential as adjuvant therapy for EC.
: Informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent for publication of the images in Figure(s) 1–7 and Table(s)1–2.
